MedPath

Neuromuscular Electrical Stimulation and Physical Function in Older Adults

Not Applicable
Conditions
Sarcopenia
Interventions
Other: NMES-Millicurrent
Registration Number
NCT03509519
Lead Sponsor
Texas State University
Brief Summary

The purpose of this placebo controlled clinical trial is to examine the effects of of neuromuscular electrical stimulation (NMES) training on physical activity, muscle function, self-efficacy, and blood markers \[e.g., brain-derived neurotrophic factor (BDNF)\] in older adults.

It is hypothesized that 4-weeks of NMES will increase 1) physical activity, 2) muscle function, 3) self-efficacy, and 4) BDNF in older adults.

Sarcopenia is a destructive progressive cycle of impaired physical function resulting in loss of muscle mass, strength, and self-confidence in ability to perform physical activities, compounded by difficulty walking and ultimately reduced physical activity levels for many older adults. Neuromuscular electrical stimulation (NMES) is a common therapeutic modality used to create involuntary muscle contractions as a means to increase muscle strength, and may be an effective treatment for improving muscle function and physical activity levels in older adults with sarcopenia. Thus, it is critical to explore viable and effective alternative therapies to increase physical activity. The goal of the investigators' is to determine the effectiveness of neuromuscular electrical stimulation (NMES) at increasing physical activity and related biological, psychological, and muscle function factors. This placebo controlled clinical trial will use a pre-test - post-test randomized experimental design.

Detailed Description

Older healthy adults (60 and older) will participate in this study. Participants will undergo 4 weeks of neuromuscular electrical stimulation (NMES) training. Participants will be randomized into the one of two groups 1) NMES-millicurrent or 2) NMES microcurrent. Participants will undergo pre- and post-training testing for muscle function, physical function, and psychological variables related to physical activity. Blood samples will also be obtained pre- and post-training.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • generally healthy men and women
  • ages 60 and older
Exclusion Criteria
    1. they have participated in regular resistance training exercise or physical rehabilitation of the lower extremity within 2 months of the study
    1. contraindicating conditions for electrical stimulation are present (i.e., swollen, infected or inflamed areas including open wounds, or painful areas on the lower limbs, implanted electronics including cardiac pacemakers, electronic infusion pumps, implanted stimulators, or surgical hardware in the lower limbs)
    1. they have current knee injury or knee pain
    1. have a neuromuscular disease
    1. currently taking insulin for diabetes regulation
    1. they have a history of seizures

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NMES-Millicurrent GroupNMES-MillicurrentNMES-millicurrent group will receive the NMES experimental treatment. Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min on each leg.
NMES-Microcurrent GroupNMES-MillicurrentThe NMES-microcurrent group will receive the Sham Treatment. The Sham Treatment will consist of electrode pad application for 40 mins on each leg, but electrical current will not be delivered. Otherwise all procedures will be the same as the NMES-millicurrent experimental group. Participants will be informed they are receiving microcurrent stimulation which is typically not felt by patients. Microcurrent stimulation is an actual type of electrical stimulation that is used therapeutically and is typically not felt by patients, however, participants will not receive this treatment. Participants will be informed of the actual treatment received at the study conclusion. Those in the Sham Group will be given the opportunity to receive the treatment at the conclusion of the study.
Primary Outcome Measures
NameTimeMethod
Change in Physical ActivityPhysical activity levels will be assessed for 1 week before the intervention and for 1 week after the intervention period. The change in physical activity will be compared between these two time-periods.

Physical activity will be measured from accelerometer data.

Secondary Outcome Measures
NameTimeMethod
Change in Muscle EnduranceMuscle endurance will be assessed prior to the first day of the intervention and 2 days after the completion of the 4-week intervention.

Muscle endurance time will be measured on a dynamometer.

Change in Muscle StrengthMuscle strength will be assessed prior to the first day of the intervention, after 2-weeks of the intervention, and two days after the completion of the 4-week intervention.

Muscle strength will be measured by maximal voluntary contraction on a dynamometer.

Change in motor activationMotor activation will be measured prior to the first day of the intervention and two days after the completion of the 4-week intervention.

Motor activation will be measured by surface electromyography measures.

Change in stair climb testThe stair cimb test test will be assessed prior to the first day of the intervention and 4 days after the last day of the 4-week intervention.

The stair climb test will assess the time it takes to safely ascend 10 stairs.

Change in arm curl testThe arm curl test will be assessed prior to the first day of the intervention and 4 days after the last day of the 4-week intervention.

The arm curl test will measure the number of repetitions completed with a dumbbell.

Pre-training NMES-related change in glucoseBlood glucose will be measured immediately before and immediately after the application of the intervention on the first (training Day 1) NMES intervention day.

Fasting blood glucose levels will be measured.

Change in perception of painPerceptions of pain will be measured immediately after the NMES treatment on the first (training day 1) and last day (training day 12) of the 4-week intervention.

Perceived pain experienced during the NMES treatment will be measured by survey.

Physical activity during the 4-week interventionPhysical activity levels will be measured during the 4 weeks of the intervention (from the first day of the intervention through the last day of the intervention).

Physical activity will be measured from accelerometer data.

Change in 6-min walk testThe 6-min walk test will be assessed prior to the first day of the intervention and 4 days after the last day of the 4-week intervention.

The 6-min walk test will assess the distance an individual can walk in 6 minutes.

Pre-training NMES-related change in Brain-derived Neurotrophic Factor (BDNF) levelsBDNF levels will be measured immediately before and immediately after the application of the intervention on the first (training Day 1) NMES intervention day.

Brain-derived neurotrophic factor, a marker of neuronal growth, will be obtained from a blood sample.

Change in self-efficacy of activities of daily livingSelf-efficacy will be measured prior to the first day of the intervention and 4 days after the last day of the 4-week intervention.

Self-efficacy will be measured by survey.

Change in five repetition sit-to-stand testThe five repetition sit-to-stand test will be assessed prior to the first day of the intervention and 4 days after the last day of the 4-week intervention.

The five repetition sit-to-stand test will assess the time it take to stand up and sit down on a chair 5 times.

Change in timed up and go testTimed up and go test will be assessed prior to the first day of the intervention and 4 days after the last day of the 4-week intervention.

The timed up and go test will measure the time it takes to stand up from a chair, walk a few meters, turn around and sit back down.

Post-training NMES-related change in glucoseBlood glucose will be measured immediately before and immediately after the application of the intervention on the last day (training day 12) of the NMES intervention.

Fasting blood glucose levels will be measured.

Post-intervention change in Brain-derived Neurotrophic Factor (BDNF) levelsBDNF levels will be measured immediately before and immediately after the application of the intervention on the last day (training day 12) of the NMES intervention.

Brain-derived neurotrophic factor, a marker of neuronal growth, will be obtained from a blood sample.

Change in grip strengthThe grip strength test will be assessed prior to the first day of the intervention and 4 days after the last day of the 4-week intervention.

The grip strength test will measure the maximal hand grip strength of both hand using a grip strength dynamometer.

© Copyright 2025. All Rights Reserved by MedPath